ESLAW logo

Estrella Immunopharma (ESLAW) Financials

Balance sheets

30 Sept 202430 June 202431 Mar 202431 Dec 202330 Sept 202331 Dec 2022

Total Assets

$3.7 M(-16.1%)$4.5 M(-48.4%)$8.6 M(-8.6%)$9.4 M(-65.5%)$27.3 M(+795.5%)$3.1 M

Current Assets

$2.2 M(-49.8%)$4.5 M(-48.4%)$8.6 M(-8.6%)$9.4 M(-65.5%)$27.3 M(+849.7%)$2.9 M

Non Current Assets

$1.5 M(+100.0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0(-100.0%)$174.4 K

Total Liabilities

$3.0 M(+1554.0%)$180.7 K(+30.5%)$138.5 K(-65.3%)$398.7 K(-97.7%)$17.3 M(+81.3%)$9.5 M

Current Liabilities

$3.0 M(+1554.0%)$180.7 K(+30.5%)$138.5 K(-65.3%)$398.7 K(-97.7%)$17.3 M(+284.1%)$4.5 M

Long Term Liabilities

$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0(-100.0%)$5.0 M

Shareholders Equity

$746.3 K(-82.5%)$4.3 M(-49.7%)$8.5 M(-6.1%)$9.0 M(-10.1%)$10.1 M(+255.5%)-$6.5 M

Book Value

$746.3 K(-82.5%)$4.3 M(-49.7%)$8.5 M(-6.1%)$9.0 M(-10.1%)$10.1 M(+255.5%)-$6.5 M

Working Capital

-$753.7 K(-117.6%)$4.3 M(-49.7%)$8.5 M(-6.1%)$9.0 M(-10.1%)$10.1 M(+722.0%)-$1.6 M

Cash And Cash Equivalents

$1.8 M(-56.9%)$4.2 M(-11.9%)$4.7 M(-47.7%)$9.0 M(-59.1%)$22.1 M(+668.7%)$2.9 M

Accounts Payable

$5000.0(+100.0%)$0.0(0%)$0.0(-100.0%)$77.1 K(-99.2%)$9.3 M(+116.6%)$4.3 M

Accounts Receivable

------

Short Term Debt

----$300.0 K-

Long Term Debt

-----$17.6 K

Total Debt

----$300.0 K(+500.0%)$50.0 K

Debt To Equity

----0.0(+400.0%)-0.0

Current Ratio

0.8(-97.0%)24.6(-60.5%)62.3(+163.2%)23.7(+1399.4%)1.6(+146.9%)0.6

Quick Ratio

------

Inventory

------

Retained Earnings

-$22.9 M(-17.3%)-$19.5 M(-25.4%)-$15.5 M(-3.1%)-$15.1 M(-7.3%)-$14.1 M(-109.3%)-$6.7 M

PB Ratio

------

Income statements

30 Sept 202430 June 202431 Mar 202431 Dec 202330 Sept 202331 Dec 2022

EPS

------

TTM EPS

------

Revenue

$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0

TTM Revenue

$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0

Total Expenses

$3.4 M(-14.5%)$3.9 M(+741.1%)$469.5 K(-54.0%)$1.0 M(-45.4%)$1.9 M(-32.1%)$2.8 M

Operating Expenses

$3.4 M(-14.5%)$3.9 M(+741.1%)$469.5 K(-54.0%)$1.0 M(-45.4%)$1.9 M(-32.1%)$2.8 M

Cost Of Goods Sold

------

TTM Cost Of Goods Sold

------

Gross Profit

------

TTM Gross Profit

------

Gross Margin

------

Operating Profit

-$3.4 M(+14.5%)-$3.9 M(-741.1%)-$469.5 K(+54.0%)-$1.0 M(+45.4%)-$1.9 M(+32.1%)-$2.8 M

TTM Operating Profit

-$8.8 M(-20.6%)-$7.3 M(-117.5%)-$3.4 M(-16.2%)-$2.9 M(+37.5%)-$4.6 M(-67.9%)-$2.8 M

Operating Margin

------

Net Income

-$3.4 M(+14.5%)-$4.0 M(-741.5%)-$469.5 K(+54.0%)-$1.0 M(+45.4%)-$1.9 M(+32.1%)-$2.8 M

TTM Net Income

-$8.8 M(-20.6%)-$7.3 M(-117.6%)-$3.4 M(-16.2%)-$2.9 M(+37.5%)-$4.6 M(-67.9%)-$2.8 M

Net Margin

------

EBIT

-$3.4 M(+14.5%)-$3.9 M(-741.1%)-$469.5 K(+54.0%)-$1.0 M(+45.4%)-$1.9 M(+32.1%)-$2.8 M

TTM EBIT

-$8.8 M(-20.6%)-$7.3 M(-117.5%)-$3.4 M(-16.2%)-$2.9 M(+37.5%)-$4.6 M(-67.9%)-$2.8 M

EBITDA

-$3.4 M(+14.5%)-$3.9 M(-741.1%)-$469.5 K(+54.0%)-$1.0 M(+45.4%)-$1.9 M(+32.1%)-$2.8 M

TTM EBITDA

-$8.8 M(-20.6%)-$7.3 M(-117.5%)-$3.4 M(-16.2%)-$2.9 M(+37.5%)-$4.6 M(-67.9%)-$2.8 M

Selling, General & Administrative Expenses

$550.7 K(+29.8%)$424.4 K(-4.5%)$444.5 K(-53.0%)$945.2 K(-31.9%)$1.4 M(+834.6%)$148.4 K

TTM SG&A

$2.4 M(-26.1%)$3.2 M(+15.3%)$2.8 M(+19.1%)$2.3 M(+51.9%)$1.5 M(+934.6%)$148.4 K

Depreciation And Amortization

--$0.0---

TTM D&A

--$0.0---

Interest Expense

------

TTM Interest Expense

------

Income Tax

$0.0(-100.0%)$1625.0(+100.0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0

TTM Income Tax

$1625.0(0%)$1625.0(+100.0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0

PE Ratio

------

PS Ratio

------

Cashflow statements

30 Sept 202430 June 202431 Mar 202431 Dec 202330 Sept 202331 Dec 2022

Cash From Operations

-$2.2 M(-660.7%)-$291.5 K(+93.1%)-$4.2 M(+62.4%)-$11.3 M(-3994.2%)-$275.2 K(-154.3%)-$108.2 K

TTM CFO

-$18.0 M(-12.1%)-$16.1 M(-1.9%)-$15.8 M(-36.7%)-$11.5 M(-2910.6%)-$383.4 K(-254.3%)-$108.2 K

Cash From Investing

$0.0(0%)$0.0(0%)$0.0(-100.0%)$5.1 M(+4617.4%)-$112.3 K(-100.0%)$0.0

TTM CFI

$5.1 M(+2.3%)$5.0 M(0%)$5.0 M(0%)$5.0 M(+4517.4%)-$112.3 K(-100.0%)$0.0

Cash From Financing

-$150.5 K(+44.3%)-$270.3 K(-221.5%)-$84.1 K(+98.8%)-$6.9 M(-134.4%)$20.0 M(+100.0%)$0.0

TTM CFF

-$7.4 M(-157.9%)$12.8 M(-2.1%)$13.1 M(-0.6%)$13.1 M(-34.4%)$20.0 M(+100.0%)$0.0

Free Cash Flow

-$2.2 M(-660.7%)-$291.5 K(+93.1%)-$4.2 M(+62.4%)-$11.3 M(-3994.2%)-$275.2 K(-154.3%)-$108.2 K

TTM FCF

-$18.0 M(-12.1%)-$16.1 M(-1.9%)-$15.8 M(-36.7%)-$11.5 M(-2910.6%)-$383.4 K(-254.3%)-$108.2 K

CAPEX

------

TTM CAPEX

------

Dividends Paid

------

TTM Dividends Paid

------

TTM Dividend Per Share

------

TTM Dividend Yield

------

Payout Ratio

------